Sarepta Therapeutics Company Profile (NASDAQ:AVII)

About Sarepta Therapeutics (NASDAQ:AVII)

Sarepta Therapeutics logoSarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD). It is focused on the development of its disease-modifying DMD drug candidates. It has received accelerated approval for its product, EXONDYS 51, indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. EXONDYS 51 is studied in clinical trials under the name of eteplirsen. Its next generation phosphorodiamidate morpholino oligomer (PMO)-based compounds are synthetic compounds that bind to complementary sequences of RNA by standard Watson-Crick nucleobase pairing. Its PMO-based chemistries are peptide conjugated PMO (PPMO), PMO-X and PMOplus.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:AVII
  • CUSIP: N/A
  • Web:
  • Trailing P/E Ratio: N/A
  • P/E Growth: N/A
  • Dividend Yield: 1.0%
  • Net Margins: -180.07%
  • Return on Equity: -62.68%
  • Return on Assets: -52.59%

Frequently Asked Questions for Sarepta Therapeutics (NASDAQ:AVII)

What is Sarepta Therapeutics' stock symbol?

Sarepta Therapeutics trades on the NASDAQ under the ticker symbol "AVII."

Who are some of Sarepta Therapeutics' key competitors?

Who are Sarepta Therapeutics' key executives?

Sarepta Therapeutics' management team includes the folowing people:

  • Douglas S. Ingram, President, Chief Executive Officer
  • Sandesh Mahatme, Executive Vice President, Chief Financial Officer and Chief Business Officer
  • David Tyronne Howton Jr., Senior Vice President, General Counsel, Corporate Secretary
  • Alexander Cumbo, Senior Vice President, Global Commercial Development
  • Shamim Ruff, Senior Vice President - Regulatory Affairs and Quality
  • Catherine Stehman-Breen M.D., Senior Vice President, Chief Medical Officer
  • Richard J. Barry, Independent Director
  • M. Kathleen Behrens Ph.D., Independent Director
  • Claude Nicaise M.D., Independent Director
  • Hans Wigzell M.D., Ph.D., Independent Director

How do I buy Sarepta Therapeutics stock?

Shares of Sarepta Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sarepta Therapeutics' stock price today?

One share of Sarepta Therapeutics stock can currently be purchased for approximately $0.66.

MarketBeat Community Rating for Sarepta Therapeutics (NASDAQ AVII)
Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  60 (Vote Outperform)
Underperform Votes:  47 (Vote Underperform)
Total Votes:  107
MarketBeat's community ratings are surveys of what our community members think about Sarepta Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Sarepta Therapeutics (NASDAQ:AVII) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A
Consensus Price Target History for Sarepta Therapeutics (NASDAQ:AVII)
Price Target History for Sarepta Therapeutics (NASDAQ:AVII)
Analysts' Ratings History for Sarepta Therapeutics (NASDAQ:AVII)
No equities research coverage for this company has been tracked by


Earnings History for Sarepta Therapeutics (NASDAQ:AVII)
No earnings announcements for this company have been tracked by


Earnings Estimates for Sarepta Therapeutics (NASDAQ:AVII)
Current Year EPS Consensus Estimate: $-0.270 EPS


Dividend History for Sarepta Therapeutics (NASDAQ:AVII)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Sarepta Therapeutics (NASDAQ:AVII)
No insider trades for this company have been tracked by


Headline Trends for Sarepta Therapeutics (NASDAQ:AVII)
Latest Headlines for Sarepta Therapeutics (NASDAQ:AVII)
DateHeadline logoSarepta Therapeutics Inc (SRPT) Stock Heads Higher on Analyst Upgrade - March 2 at 1:31 PM logoSarepta Under Pressure As FDA Approves Marathon Pharma's Emflaza For DMD Treatment - February 9 at 3:46 PM logoSarepta Soars Following Encouraging Exondys 51 News - January 10 at 12:48 PM logoNoteworthy Wednesday Option Activity: SRPT, DAL, C - December 14 at 5:43 PM logoSarepta Shares Fall After Anthem Blue Cross Finds Issue With Eteplirsen - October 7 at 12:54 PM logoSarepta Wins Exclusive License, Collaboration Deal for European Rights To Summit's DMD Drug - October 4 at 10:21 AM logoSarepta Dosing First Patients In Phase 3 Trial Of Duchenne Muscular Dystrophy Drug - September 29 at 8:19 AM logoBetter Buy: BioMarin Pharmaceuticals Inc. vs. Sarepta Therapeutics Inc - September 28 at 1:16 PM logo3 Reasons Sarepta Shares Rallied Following News Of $225 Million Offering - September 22 at 3:49 PM logoFDA Commish Says Sarepta's DMD Study Should Be Retracted - September 22 at 10:58 AM logoWhy Infoblox Inc (BLOX), Isle of Capri Casinos (ISLE) and Sarepta Therapeutics Inc (SRPT) Are 3 of Today’s Best Stocks - September 19 at 5:58 PM logoSarepta Analysts Turn Bullish After Duchenne Muscular Dystrophy Drug Eteplirsen Gets Approval - September 19 at 3:50 PM logoOppenheimer Weighs In on Sarepta's Eteplirsen - September 19 at 12:47 PM logoWhy Monsanto Company (MON), Sarepta Therapeutics Inc (SRPT) and VF Corp (VFC) Are 3 of Today’s Worst Stocks - September 15 at 4:54 PM logoIndia close to signing Rafale jet deal: government official - September 15 at 12:33 PM logoExclusive: Dr. Ron Farkas, Eteplirsen's Harshest Critic, Has Left The FDA - September 13 at 9:48 PM logoNoteworthy Friday Option Activity: SRPT, NUS, IBM - August 5 at 12:31 PM logoWatch These 10 Huge Put Purchases In Thursday Trade - July 28 at 3:54 AM logoSarepta Therapeutics Inc's Stock Has Plunged 47% in 2016. Here's Why. - July 4 at 8:24 AM logoShort Interest In Sarepta Therapeutics Moves 15% Higher - February 27 at 2:50 PM logoHere Is Why Sarepta Therapeutics Inc Slid Today - February 9 at 2:33 PM logoSarepta Therapeutics (SRPT) PDUFA for Eteplirsen Extended - February 8 at 2:40 PM logoCovered Call Alerts For Apple, Sarepta Therapeutics, Freeport-McMoRan, PayPal Holdings Inc. and Vuzix Corporation Released By InvestorsObserver - February 4 at 2:55 PM logoSarepta Therapeutics Inc. (SRPT) Plunged To An 8-Month Low - January 20 at 2:23 PM logoSarepta Therapeutics Inc. (SRPT) Is Sinking After FDA Rejects BioMarin Drug - January 17 at 1:55 PM logoSarepta Therapeutics Made Investors Millionaires in 2 Years - August 14 at 12:01 PM



Sarepta Therapeutics (AVII) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.